May 13, 2021
– Completed successful $202.4 million Initial Public Offering (IPO); cash and marketable securities of $309.9 million as of March 31, 2021 – – Initiated Phase 1 MAD study of EDG-5506, a small molecule drug candidate designed to arrest muscle fiber Read more…
